Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
Date:7/14/2008

to meet its financial obligations beyond fiscal year 2009 without access to additional cash and cash equivalents. Nasdaq Marketplace Rule 4350(b)(1)(B) requires Nasdaq-listed companies to publicly announce through the news media the receipt of an audit opinion containing a "going concern" qualification. The company's Annual Report on Form 10-K will be filed later today and will be available at the SEC's website at http://www.sec.gov, or through the investor portion of Peregrine's website at http://www.peregrineinc.com.

Paul Lytle, chief financial officer of Peregrine, noted, "Based on a combination of projected cash inflows from the anticipated funding from the government DTRA contract and our projected FY 2009 revenues from Avid, which we project to be in excess of $10 million based on current signed contracts from third-party customers, we believe the company has sufficient financial resources to meet its obligations through at least FY 2009. While we feel confident about our likely cash inflows from these contracts over the next 12 months, there are potential uncertainties associated with these financial projections that required the company's independent registered public accounting firm to include a going concern qualification in its audit opinion. We remain confident that should we need to raise additional funds, these funds could be raised through a debt financing or equity offering, with the possibility that future market conditions could be significantly better. We therefore expect this qualified opinion that was required from our auditors will have minimal effect on the company as we advance our programs and continue to service our Avid customers."

Corporate Highlights Since the Start of Fiscal Year 2008

-- In July 2008, Peregrine reported positive early results from the first cohort of patients enrolled in its Phase II trial of bavi
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
2. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
3. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
4. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
7. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
11. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... -- Scientists, including University of Oregon chemist Geraldine ... scaffolds of self-assembling, synthetic proteins called peptoid nanosheets ... The accomplishment -- detailed this week in a ... Proceedings of the National Academy of Sciences ... design of the two-dimensional peptoid nanosheets that can ...
(Date:9/2/2014)... Sept. 2, 2014  TransCelerate BioPharma Inc. ("TransCelerate") ... approach for protecting personal data in Clinical Study ... and others. The document describes an approach to ... CSRs and other related clinical trial documents, and ... goal of the TransCelerate CSR Redaction approach is ...
(Date:9/2/2014)... PA (PRWEB) September 02, 2014 ... a new highly efficient, cost effective approach to ... Patent No. 8,820,265 by the U.S. Patent and ... to Opertech. , “Opertech’s taste evaluation ... the first automated high throughput system for rapid ...
(Date:9/2/2014)... 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY ) announced ... Executive Officer, will present at the Rodman & Renshaw 16 ... York on Tuesday, Sept. 9, 2014 at 2:05 ... of the presentation will be accessible by visiting the Oncothyreon ... About Oncothyreon Oncothyreon is ...
Breaking Biology Technology:UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2
... , SUNNYVALE, Calif., Oct. 13 Cepheid (Nasdaq: CPHD ... its third quarter ended September 30, 2009, on Wednesday, October ... company will host a management presentation at 2 p.m. Pacific ... To access the live webcast, please visit Cepheid,s website ...
... Novavax, Inc. (Nasdaq: NVAX ) announced today that it ... from the National Institute of Allergy and Infectious Diseases (NIAID) ... from the NIAID is to support a segment of the ... particle-based vaccine. RSV is the most commonly identified cause ...
... CAMBRIDGE, Mass., Oct. 13 Cequent Pharmaceuticals, a pioneer ... treatments to prevent and treat human disease, announced that ... Cequent,s planned launch of its clinical program and highlight ... for 3 p.m. on Tuesday, October 27, 2009, at ...
Cached Biology Technology:Cepheid Schedules 2009 Third Quarter Financial Results Announcement and Webcast 2Novavax Awarded NIH Grant for Respiratory Syncytial Virus (RSV) Vaccine Program 2Novavax Awarded NIH Grant for Respiratory Syncytial Virus (RSV) Vaccine Program 3Cequent to Provide Details at BIOCOM About Planned Launch of its Clinical Program - 3 p.m., Tuesday, October 27 2
(Date:9/2/2014)... September 2, 2014 Best-selling author Sam Kean stops ... the Megalodon, the 50-foot super shark that, despite what ... extinct. Learn all about it at http://youtu.be/KhFygIoW_MA . ... Tales of Madness, Love and the History of the ... getting the Reactions treatment in a 10-episode video series ...
(Date:9/2/2014)... done in by it. New research at Rockefeller University ... gap in mice with very similar genetic backgrounds ... the development of psychiatric disorders such as anxiety and ... as it goes through its life. And we suspect ... genes, and as a result, affect an animal,s susceptibility ...
(Date:9/1/2014)... the U.S. undergoes a battery of tests designed to ... Thousands of children born in the developing world, however, ... the disease each year. , A.J. Kumar hopes ... those deaths. , A Post-Doctoral Fellow in Chemistry ... Whitesides, the Woodford L. and Ann A. Flowers University ...
Breaking Biology News(10 mins):Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3Faster, cheaper tests for sickle cell 2Faster, cheaper tests for sickle cell 3
... school students and teachers sounds like a witches brew for an ... Instead, these are the components that comprise the ... developed by researchers at Washington University in St. Louis and a ... Lars Angenent, Ph.D., assistant professor of ...
... a pair of proteins that work in concert to restart ... dormancy. The Hawley Lab has described the dual ... that awakens the long-dormant egg, allowing for production of a ... Dec. 4, 2007 issue of PLoS Biology. The ...
... may have begun in the protected spaces inside of layers ... new hypothesis. The hypothesis was developed by Helen Hansma, ... and a program director at the National Science Foundation. Hansma ... Dec. 4, at the annual meeting of the American Society ...
Cached Biology News:Microbial fuel cells turn on the juice 2Microbial fuel cells turn on the juice 3Stowers Institute's Hawley Lab identifies factors responsible for restart of meiotic cycle 2New hypothesis for origin of life proposed 2
... Blot Processing Standard Tray (3 ... for gel staining and blot processing.Automated ... gels for proteins and nucleic acid ... detection and chromogenic detection.Programmable control of ...
... Dithiothreitol, 1 g. High quality ... sample preparation that give consistent ... cells and tissues.Clean up samples ... volumes. Accurately quantitate protein for ...
IMAGEQUANT 300 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
ANTI MYCOBACTERIUM TUBERCULOSIS...
Biology Products: